Niacin Trial Halted Due to Stroke Concerns

In Cardio
Mon, 30 May 2011

A trial of extended-release niacin on top of statin therapy in patients with a history of CVD, high triglycerides, and low levels of HDL cholesterol has been halted prematurely, 18 months ahead of schedule, because niacin offered no additional benefits in this patient population. There was also a small, unexplained increase in ischemic stroke in the niacin group, but patients are being urged not to discontinue niacin without consulting their doctor.

«« Heart Attacks Declining, Rising BMI May Cause Increase

Rhesus Healthcare to Partner CathMedical's Picasso CIS »»

Latest Articles

Decision-Making in the ICU
- Journal Article
- 19/04/2024
Decision-making in the ICU is a multifaceted process that involves clinical assessment, collaboration among multidisciplinary teams, ethical considerations, evidence-based practice, communication, and continuous adaptation to evolving clinical scenarios. Balancing the complex factors requires
READ MORE
Dealing With Uncertainty in ICU Decision-Making: A Practical Guide
- Journal Article
- 19/04/2024
When the stakes are high, and the path ahead is uncertain, the decisions made, especially if a patient continues to worsen, can be sources of self-torment and can haunt us for a long time. Our goal is to suggest ways to steer decision-making for intensivists in the face of uncertainty by prop
READ MORE
The Least Bad Decision: Crisis Standards of Care After the Pandemic
- Journal Article
- 19/04/2024
COVID-19 was an emergency that lasted for years and left few regions of the world untouched. The pandemic shone a spotlight on both the strengths and weaknesses of our disaster planning. What worked, what did not, and how can we better plan for future emergencies? The COVID-19 pandemic fo
READ MORE

A trial of extended-release niacin on top of statin therapy in patients with a history of CVD, high triglycerides, and low levels of HDL cholesterol has b...